A 51-year-old man died last month after receiving an experimental treatment from Sarepta, the third death this year tied to ...

Second patient death reported with gene therapy for muscular dystrophy BY Associated Press Washington, D.C. PUBLISHED 4:05 PM ET Jun. 16, 2025 PUBLISHED June 16, 2025 @4:05 PM ...

Drugmaker Sarepta Therapeutics says it won’t comply with a request from U.S. regulators to halt all shipments of its gene ...

WASHINGTON (AP) — Shares of Sarepta Therapeutics plunged Monday after the biotech drugmaker reported a second death in connection with its gene therapy for muscular dystrophy.

Second patient death from liver failure after Sarepta's Elevidys gene therapy triggers FDA investigation. Stock crashes 41% ...

WASHINGTON (AP) — Shares of Sarepta Therapeutics plunged Monday after the biotech drugmaker reported a second death in connection with its gene therapy for muscular dystrophy.

On an investor call Friday, analysts grilled the company over its apparent lack of transparency on the matter.

The U.S. Food and Drug Administration ( FDA) has placed an immediate clinical hold on Sarepta Therapeutics' investigational ...

The European Union’s health regulatory agency did not endorse approving Elevidys for ambulatory patients with Duchenne ...

Shortly after the U.S. FDA announced an investigation into the death of a patient who had received Elevidys, a gene therapy ...

The U.S. Food and Drug Administration said on Friday it was investigating the death of an eight-year-old boy who received ...